GlobeNewsWire
19 Mar 2026, 23:21 UTC · 32w ago
Verdict
Headline takes no side. We score CLLS +0.80 — strongly bullish.
+0.80strongly bullish
More positive than 87% of ticker scores this week
Which stocks this story touches
More positive than 87% of ticker scores this week
Reported strong efficacy results for lasme-cel with a 100% overall response rate and increased annual revenues.
More positive than 53% of ticker scores this week
Mentioned as a partner in a Joint Research and Collaboration Agreement that drove revenue growth for Cellectis.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 74% of relationship scores this week
[mutual] Cellectis and AstraZeneca have a Joint Research and Collaboration Agreement.
More positive than 54% of relationship scores this week
[mutual] Cellectis partners with Allogene for Anti-CD19 and Anti-CD70 CAR-T therapies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
13h ago
−69.0%
Price is moving against the score
$1.08 vs $3.48 close before publication (Mar 19) · not market-adjusted
CLLS chart →
